Flurbiprofen (DB00712): A Comprehensive Pharmacological and Clinical Monograph

I. Introduction and Drug Profile

1.1. Overview and Classification

Flurbiprofen is a potent small molecule drug classified as a nonsteroidal anti-inflammatory drug (NSAID).[1] It is a member of the phenylalkanoic acid derivative family and, more specifically, a propionic acid derivative. This classification places it in the same chemical and pharmacological class as other widely used NSAIDs such as ibuprofen, naproxen, and ketoprofen.[1] As a member of this class, Flurbiprofen exhibits a triad of core therapeutic actions: anti-inflammatory, analgesic (non-narcotic), and antipyretic properties, making it a versatile agent for the management of a spectrum of conditions characterized by pain and inflammation.[1]

The drug's development traces back to the highly productive research period of the 1960s at the research arm of Boots UK, which also yielded the discovery of several other foundational NSAIDs, including ibuprofen.[2] Flurbiprofen was patented in 1964 and, following extensive clinical development, received its initial approval for medical use in 1987, with approval in the United States by the Food and Drug Administration (FDA) following in 1988.[2] This historical context establishes Flurbiprofen as one of the classic, well-characterized NSAIDs that form the bedrock of anti-inflammatory pharmacotherapy. It is available in diverse formulations, including oral tablets for systemic conditions, ophthalmic solutions for ocular surgery, and oromucosal preparations for localized throat pain, reflecting its broad clinical utility.[1]

1.2. Chemical Identity and Physicochemical Properties

A thorough understanding of Flurbiprofen's chemical and physical characteristics is fundamental to appreciating its formulation, pharmacokinetic behavior, and interaction with biological systems.

Nomenclature and Structure